Vitae Biomedical Co., Ltd. has developed an innovative diagnostic solution, the “Urine-Based Lung Cancer Antigen Detection Reagent,” designed to enable accurate and accessible lung cancer screening through a non-invasive approach.

At the core of the product is a proprietary antibody technology integrated with an optimized sandwich enzyme-linked immunosorbent assay (ELISA) design. This combination allows for precise identification of lung cancer-related biomarkers in urine samples, supporting earlier detection and timely clinical intervention.

Unlike conventional testing methods, the assay is designed around urine sampling, eliminating the need for invasive procedures, appointment scheduling, or specialized medical personnel for sample collection. This significantly reduces barriers to screening while improving patient comfort and compliance.

Technical Features

• Broad subtype coverage: Applicable across major lung cancer subtypes, including adenocarcinoma, squamous cell carcinoma, and small cell lung cancer.
• High-affinity antibodies: Proprietary antibody design minimizes cross-reactivity and reduces detection interference.
• High accuracy: Demonstrates an accuracy rate of approximately 80–90%, supporting reliable clinical decision-making.
• Clinical compatibility: Designed to integrate with standard laboratory workflows, making it accessible to hospitals and health screening centers.

Competitive Advantages

• Lower screening barriers: Non-invasive urine sampling increases accessibility across age groups and health conditions.
• Improved efficiency and cost-effectiveness: No appointment required, with total turnaround time within 10 days and assay processing time of approximately 4–5 hours.
• Supports longitudinal monitoring: Safe and repeatable sampling enables frequent testing, making it suitable for follow-up and ongoing patient management.

The product has begun attracting attention from healthcare professionals and institutions both domestically and internationally. Collaborative efforts are underway with partners in Singapore, Japan, and Thailand to further expand its clinical adoption and market reach.